Powerful IOP Reduction

For patients who may benefit from a preservative-free treatment, ZOLYMBUS™ demonstrated IOP reduction consistent with PGA expectations in a US Phase III study.1-3

US PHASE III STUDY

Forest plot showing similar reductions in mean IOP with preservative-free bimatoprost 0.01% gel and bimatoprost 0.01% over 12 weeks in a US Phase III study; mean IOP reduction at Week 12 was 8.09 mmHg.
Table showing Week 12 mean IOP reductions of approximately 27–34% across all measurement times in the US Phase III study, with up to 33% reduction observed

US Phase III study methodology: Prospective, multicenter, randomized, investigator-masked Phase III non-inferiority trial in 464 patients with OAG or OHT comparing preservative-free bimatoprost 0.01% gel with bimatoprost 0.01% over 12 weeks. Following a washout period of up to 7 weeks depending on prior therapy, IOP was measured at 8 AM, 10 AM, and 4 PM at baseline and Weeks 2, 6, and 12; safety and tolerability were assessed throughout.2